title: 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid.
abstract: Pulmonary carcinoids cause serious difficulties in imaging diagnostics in all stages of the disease. SRS holds great promise for detecting occult primary tu and metastatic lesions. (99m)Tc-EDDA/HYNIC-octreotate, a new scintigraphic agent, should significantly improve sensitivity of the diagnostics of carcinoids due to better affinity to SSR2 than (111)In-Octreoscan and the higher count rate obtained from (99m)Tc over (111)In. We present a case of a 40-year-old women operated on because of lung carcinoid tumour in 2002. The symptoms did not resolve after the operation and 5-OHIAA was still elevated. The thorax spiral CT revealed the focal lesion beneath carina. (111)In-Octreoscan and (99m)Tc-EDDA/HYNIC-octreotate SRS revealed two focal lesions in the mediastinum. (99m)Tc-EDDA/HYNIC-octreotate detected two additional lesions in the lower part of the right lung. Target/non-target count ratios of the lesions were as follows: (99m)Tc-EDDA/HYNIC-octreotate scans - 2,9, (111)In-Octreoscan- 2,1. PET-FDG examination revealed no pathology. Owing to severe bone pains and carcinoid symptoms the patient was referred for the 90Y-DOTA-octreotate treatment.
  
  
  CONCLUSIONS
  SRS with a new 99mTc marked somatostatin analogue - octreotate allows for a more sensitive detection of metastatic leasions in carcinoid tumours. The usefulness of 18F-FDG PET, widely used as a powerful imaging technique in clinical oncology, is limited in detection of carcinoid tumours due to the low proliferative activity.
authors.affiliation: Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland. alahub@cm-uj.krakow.pl
authors.forename: A
authors.initials: A
authors.lastname: Hubalewska-Dydejczyk
authors.forename: K
authors.initials: K
authors.lastname: Fröss-Baron
authors.forename: F
authors.initials: F
authors.lastname: Gołkowski
authors.forename: A
authors.initials: A
authors.lastname: Sowa-Staszczak
authors.forename: R
authors.initials: R
authors.lastname: Mikołajczak
authors.forename: B
authors.initials: B
authors.lastname: Huszno
mesh_terms: D000328:Adult; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000628:therapy; D004492:Edetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D006834:Hydrazines; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary / Q000628:therapy; D009362:Neoplasm Metastasis; D009539:Nicotinic Acids; D015609:Organotechnetium Compounds / Q000008:administration & dosage; D011859:Radiography; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: C120392:6-hydrazinopyridine-3-carboxylic acid; D006834:Hydrazines; D009539:Nicotinic Acids; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013004:Somatostatin; C026058:EDDA; D004492:Edetic Acid; C081788:pentetreotide